Evidence map›Paper›PMID 37094184›Full record

ArticleRheumatology (Oxford, England)2024

Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort.

Xenofon Baraliakos, Effie Pournara, Laura C Coates, Victoria Navarro-Compán, Ricardo Blanco, Eamonn O'Brien, Barbara Schulz, Robert Landewe

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02721966 (MAXIMISE), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02721966 phase3completednot on this map

MAXIMISE (Managing AXIal Manifestations in PsorIatic Arthritis With SEcukinumab), a Randomized, Double-blind, Placebo-controlled, Multicenter, 52-week Study to Assess the Efficacy and Safety of Secukinumab 150 mg or 300 mg s.c. in Participants With Active Psoriatic Arthritis and Axial Skeleton Involvement Who Have Inadequate Response to Non-steroidal Anti-inflammatory Drugs (NSAIDs)

TypeinterventionalSponsorNovartis PharmaceuticalsRan2016 to 2019Enrolled503ConditionsAxial Psoratic ArthritisArmsSecukinumab, Secukinumab and Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Imaging in psoriatic arthritis: established methods and emerging techniques.Therapeutic advances in musculoskeletal disease · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 6 countries.

Xenofon BaraliakosRheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany.ORCID 0000-0002-9475-9362
Effie PournaraNovartis Pharma AG, Immunology, Hepatology and Dermatology, Basel, Switzerland.
Laura C CoatesNuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.ORCID 0000-0002-4756-663X
Victoria Navarro-CompánDepartment of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain.ORCID 0000-0002-4527-852X
Ricardo BlancoDivisions of Immunology, Endocrinology, and Rheumatology, Hospital University Marqués de Valdecilla, Santander, Spain.
Eamonn O'BrienNovartis Ireland Limited, Dublin, Ireland.
Barbara SchulzNovartis Pharma AG, Immunology, Hepatology and Dermatology, Basel, Switzerland.
Robert LandeweDepartment of Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.
Novartis (Switzerland) · CHAmsterdam UMC Location University of Amsterdam · NLMarqués de Valdecilla University Hospital · ESNovartis (Ireland) · IENuffield Orthopaedic Centre · GBRheumazentrum Ruhrgebiet · DE

Funding

Astra-ZenecaNovartis Pharma AG
6 · The paper itself

Abstract

objectiveThe current analysis of the MAXIMISE trial was conducted to investigate the presence of post-inflammatory and degenerative spinal changes and inflammatory changes in spinal processes identified in baseline MRIs and their potential for predicting differential treatment effects in a cohort of PsA patients with axial manifestations.

methodsBaseline spinal MRIs from the MAXIMISE trial were re-read to identify additional inflammatory (spinal process), post-inflammatory, and degenerative changes, and investigate the differential treatment effect of these imaging features using logistic regression modelling.

resultsIn addition to bone marrow oedema assessed at primary analysis, spinal process inflammation and post-inflammatory changes evaluated by FAt Spondyloarthritis Spine Score were documented in 11.1% and 20.2% patients, respectively. At least one type of degenerative change was noted in 64% patients, with Pfirrmann grade ≥3 (51.1%) being the most common. Combining primary and re-read MRI findings, 67.1% of patients presented with inflammatory or post-inflammatory changes while 21.2% had degenerative changes alone. Although not statistically significant, post-inflammatory changes were associated with a trend for better efficacy outcomes in terms of ASAS20, ASAS40 and BASDAI50 responses; a trend for worse outcomes was observed in the presence of degenerative changes.

conclusionThe current analysis revealed the occurrence of additional inflammatory and post-inflammatory changes suggestive of axial PsA (axPsA) and a trend for better clinical outcomes for patients treated with secukinumab. These results elucidate the imaging characteristics and improve our current understanding of axPsA thereby supporting the interpretation of future trials.

trial registrationClinicalTrials.gov, NCT02721966.

Indexed as

Arthritis, PsoriaticSpondylarthritisHumansInflammationMagnetic Resonance ImagingSpineaxial manifestationdegenerative changesinflammatorypost-inflammatoryPsA

Identifiers

PMID37094184
PMCPMC10765145
OpenAlexW4366816225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.